Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026

OD-001 met Phase 2a endpoints, but pivotal trial results are nearly two years away.

What the company is saying

Odyssey Therapeutics is highlighting positive results from the completed induction period of its Phase 2a trial for OD-001, an oral RIPK2 inhibitor, in moderate-to-severe ulcerative colitis. The company emphasizes that the trial met its primary endpoint, with a mean reduction of 2.4 points in modified Mayo score at Week 12 (p<0.001), and reports clinical remission, response, and symptomatic remission rates of 27%, 61%, and 49% respectively at the 20 mg BID dose. Management, led by founder and CEO Gary D. Glick, Ph.D., frames these results as both clinically meaningful and mechanistically validated, citing biomarker and transcriptomic evidence consistent with RIPK2 inhibition. The announcement stresses tolerability, with no serious adverse events or treatment-related discontinuations, and only three mild drug-related events in the higher-dose group. Odyssey is positioning 20 mg BID as the lowest maximally efficacious dose for future development. The company is explicit that the trial was open-label and lacked a placebo control, and that the data remain subject to change until database lock. The narrative is confident, but acknowledges that the next steps are randomized, double-blind trials with topline results not expected until the second half of 2027.

What the data suggests

The Phase 2a induction analysis included 56 efficacy-evaluable patients, with 41 in the 20 mg BID group and 15 in the 10 mg BID group. At Week 12, the 20 mg BID group achieved a clinical remission rate of 27%, clinical response of 61%, and symptomatic remission of 49%. The 10 mg BID group saw lower rates: 20% remission, 40% response, and 27% symptomatic remission. Symptomatic remission at 20 mg BID was 21% as early as Week 2, rising through Week 12. In subgroups, clinical remission at 20 mg BID was 29% in advanced therapy-naïve patients and 23% in advanced therapy-experienced patients, and 16% in those with the most severe endoscopic disease (MES of 3). The trial met its primary endpoint with a mean reduction of 2.4 points in modified Mayo score (p<0.001). Safety data show no serious adverse events or treatment-related discontinuations, with three mild drug-related events (two fevers, one headache) at 20 mg BID and one unrelated Grade 3 anemia at 10 mg BID. The trial was open-label, with no concurrent placebo control, and the data are not yet locked. No financial figures, revenue, or cash metrics are disclosed. The evidence supports pharmacologic activity and a favorable safety profile for OD-001, but the absence of a control arm and the open-label design limit the strength of efficacy conclusions.

Analysis

The announcement provides detailed, quantitative results from a completed Phase 2a induction period, including specific remission and response rates, adverse event counts, and biomarker trends. The majority of claims are realised and supported by disclosed data, with only two forward-looking statements regarding future trials and expected topline results in the second half of 2027. There is no evidence of exaggerated language or narrative inflation; the tone is positive but proportionate to the results. No large capital outlay or immediate financial impact is disclosed, and the next clinical milestones are long-term (over 18 months away). The absence of financial metrics is not a deficiency here, as this is a pre-commercial, clinical-stage biotech update. The only minor inflation is in the qualitative description of biomarker trends without numerical/statistical detail.

Risk flags

• ●The open-label design and lack of a concurrent placebo control in the Phase 2a trial increase the risk that observed efficacy is influenced by bias or placebo effect, which may not be replicated in future double-blind, controlled studies.
• ●The disclosed efficacy rates, while promising, are based on a relatively small sample (n=41 at 20 mg BID) and may not generalize to larger or more diverse patient populations.
• ●The timeline to the next major catalyst is long, with topline results from pivotal trials not expected until the second half of 2027, exposing investors to extended development risk and potential changes in competitive or regulatory landscape.
• ●No financial data, cash runway, or funding plans are disclosed, leaving uncertainty about the company’s ability to finance ongoing and future clinical trials through to these long-dated milestones.

Bottom line

Odyssey Therapeutics has delivered positive Phase 2a induction results for OD-001 in ulcerative colitis, with the drug meeting its primary endpoint and showing clinical remission rates of 27% at the 20 mg BID dose. Safety appears favorable, with no serious adverse events or treatment-related discontinuations. However, the trial's open-label, non-placebo-controlled design limits the strength of these efficacy claims, and the small sample size increases uncertainty. The next pivotal data will not be available until the second half of 2027, meaning investors face a long wait for confirmatory results that could drive regulatory or commercial value. No financial or funding details are provided, so the company’s ability to sustain operations through this period is unclear. The most important takeaway is that while the clinical signal is encouraging, the true value of OD-001 will only be determined by larger, controlled trials with results nearly two years away.

Announcement summary

(NASDAQ:ODTX) Odyssey Therapeutics, Inc. announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with moderate-to-severe ulcerative colitis. The results were presented at United European Gastroenterology (UEG) Week in Barcelona, Spain. The completed OD-001 induction analysis included all 56 efficacy-evaluable patients. The trial met its primary endpoint of change from baseline in modified Mayo score at Week 12, with a mean reduction of 2.4 points across the evaluable population (p<0.001). At Week 12, clinical remission, clinical response, and symptomatic remission rates were 27%, 61%, and 49%, respectively, in the pooled 20 mg BID group (n=41), and 20%, 40%, and 27%, respectively, at 10 mg BID (n=15). In the 20 mg BID group, fecal calprotectin trended lower, hsCRP and circulating neutrophils were significantly decreased, and serum albumin significantly increased. Symptomatic remission at 20 mg BID reached 21% at Week 2, increasing throughout the induction period with no plateau observed through Week 12. After 12 weeks of treatment with OD-001, clinical remission at 20 mg BID was 29% in advanced therapy-naïve (n=28) and 23% in advanced therapy-experienced (n=13) patients. Clinical remission at Week 12 for patients taking OD-001 at 20 mg BID was 16% in patients with a Mayo Endoscopic Score (MES) of 3 (n=19). Exploratory analyses of paired colonic biopsies from baseline and Week 12 showed reductions in RIPK2-responsive and downstream inflammatory gene signatures, including IL-23, TNF/NF-κB, TL1A, AP-1 and T-cell-associated pathways. Reductions in fibrosis-associated signatures and increased expression of genes linked to epithelial homeostasis and mucosal healing were observed. Exploratory patient-level comparisons with published datasets of approved therapies suggest OD-001 modulates RIPK2-associated pathways beyond general mucosal improvement achieved with other agents. OD-001 was generally well tolerated during the 12-week induction period, with no serious adverse events, serious infections, treatment-related discontinuations, or treatment-emergent liver function abnormalities. Three adverse events in the 20 mg BID group were considered drug-related (two fevers and one headache). One Grade 3 anemia event in the 10 mg BID group occurred in a patient with pre-existing anemia, was considered unrelated to treatment, and resolved with iron supplementation without discontinuing OD-001. The Phase 2a trial (NCT06850727) used an open-label, dose-ranging design with 10 mg and 20 mg BID dosing, and the primary endpoint was change from baseline in the three-component modified Mayo score. The trial had no concurrent placebo control, and the data remain subject to change until database lock. Odyssey plans to advance OD-001 into a randomized, placebo-controlled Phase 2b monotherapy trial and a randomized, active-controlled Phase 2a trial evaluating OD-001 plus vedolizumab versus vedolizumab plus placebo. Both studies will be double-blind, with topline induction results expected in the second half of 2027. Odyssey will host a conference call and webcast to discuss the completed Phase 2a induction results, including additional analyses beyond those presented at UEG.

Disagree with this article?